The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice

European Journal of Pharmacology

Volumn 723, Issue 1, 2014, Pages 207-215

  Fukuda Tsuru, Sayaka ^a   Kakimoto, Tetsuhiro ^a   Utsumi, Hiroyuki ^a   Kiuchi, Satoko ^a   Ishii, Shinichi ^a  

^a Department i   (Japan)

Author keywords

Adipocyte hypertrophy; Dipeptidyl peptidase 4; Energy expenditure; Hepatic steatosis; Insulin resistance; Obesity

Indexed keywords

ADIPOCYTE HYPERTROPHY; DIPEPTIDYL PEPTIDASE-4; ENERGY EXPENDITURE; HEPATIC STEATOSIS; INSULIN RESISTANCE; OBESITY;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; ANTI-OBESITY AGENTS; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENERGY METABOLISM; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; OBESITY; ORGAN SIZE; OXYGEN CONSUMPTION; PYRAZOLES; THIAZOLIDINES; WEIGHT GAIN;

EID: 84893771907     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.11.030     Document Type: Article

References (44)

1. B. Ahren DPP-4 inhibitors Best. Pract. Res. Clin. Endocrinol. Metab. 21 2007 517 533 (Pubitemid 350185859)
2. B. Ahren, H. Larsson, and J.J. Holst Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus J. Clin. Endocrinol. Metabol. 82 1997 473 478 (Pubitemid 27068614)
3. A.D. Attie, and P.E. Scherer Adipocyte metabolism and obesity J. Lipid Res. 50 Suppl. 2009 S395 S399
4. R. Buettner, J. Scholmerich, and L.C. Bollheimer High-fat diets: modeling the metabolic disorders of human obesity in rodents Obesity (Silver Spring) 15 2007 798 808 (Pubitemid 46740952)
5. H.C. Chen, and R.V. Farese Jr. Determination of adipocyte size by computer image analysis J. Lipid Res. 43 2002 986 989 (Pubitemid 34602622)
6. C.H. Chien, L.H. Huang, C.Y. Chou, Y.S. Chen, Y.S. Han, G.G. Chang, P.H. Liang, and X. Chen One site mutation disrupts dimer formation in human DPP-IV proteins J. Biol. Chem. 279 2004 52338 52345 (Pubitemid 39656609)
7. J.C. Clapham, J.R. Arch, H. Chapman, A. Haynes, C. Lister, G.B. Moore, V. Piercy, S.A. Carter, I. Lehner, S.A. Smith, L.J. Beeley, R.J. Godden, N. Herrity, M. Skehel, K.K. Changani, P.D. Hockings, D.G. Reid, S.M. Squires, J. Hatcher, B. Trail, J. Latcham, S. Rastan, A.J. Harper, S. Cadenas, J.A. Buckingham, M.D. Brand, and A. Abuin Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean Nature 406 2000 415 418 (Pubitemid 30625561)
8. S.L. Conarello, Z. Li, J. Ronan, R.S. Roy, L. Zhu, G. Jiang, F. Liu, J. Woods, E. Zycband, D.E. Moller, N.A. Thornberry, and B.B. Zhang Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc. Natl. Acad. Sci. U.S.A. 100 2003 6825 6830 (Pubitemid 36666664)
9. A.D. Dobrian, Q. Ma, J.W. Lindsay, K.A. Leone, K. Ma, J. Coben, E.V. Galkina, and J.L. Nadler Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice Am. J. Physiol. - Endocrinol. Metab. 300 2011 E410 E421
10. E. Doucet, and A. Tremblay Food intake, energy balance and body weight control Eur. J. Clin. Nutr. 51 1997 846 855 (Pubitemid 27514240)
11. D.J. Drucker The role of gut hormones in glucose homeostasis J. Clin. Investig. 117 2007 24 32 (Pubitemid 46048446)
12. T. Eto, S. Inoue, and T. Kadowaki Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial Diabetes, Obes. Metab. 14 2012 1040 1046
13. J.N. Feige, and J. Auwerx Transcriptional coregulators in the control of energy homeostasis Trends Cell Biol. 17 2007 292 301 (Pubitemid 46829846)
14. J. Folch, M. Lees, and G.H. Sloane Stanley A simple method for the isolation and purification of total lipides from animal tissues J. Biol. Chem. 226 1957 497 509
15. S. Fukuda-Tsuru, J. Anabuki, Y. Abe, K. Yoshida, and S. Ishii A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations Eur. J. Pharmacol. 696 2012 194 202
16. K. Hara, M. Horikoshi, T. Yamauchi, H. Yago, O. Miyazaki, H. Ebinuma, Y. Imai, R. Nagai, and T. Kadowaki Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome Diabetes Care 29 2006 1357 1362 (Pubitemid 44125935)
17. J.J. Holst Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1 Diabetes/Metab. Res. Rev. 18 2002 430 441 (Pubitemid 36041598)
18. J.J. Holst, and C.F. Deacon Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol. Metab. 24 2013 145 152
19. B.B. Kahn, and J.S. Flier Obesity and insulin resistance J. Clin. Investig. 106 2000 473 481 (Pubitemid 30666380)
20. M. Kern, N. Kloting, H.G. Niessen, L. Thomas, D. Stiller, M. Mark, T. Klein, and M. Bluher Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity PloS One 7 2012 e38744
21. M.K. Kim, Y.N. Chae, H.D. Kim, E.K. Yang, E.J. Cho, S.H. Choi, Y.H. Cheong, H.S. Kim, H.J. Kim, Y.W. Jo, M.H. Son, S.H. Kim, and C.Y. Shin DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes Life Sci. 90 2012 21 29
22. A.M. Lambeir, C. Durinx, S. Scharpe, and I. De Meester Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit. Rev. Clin. Lab. Sci. 40 2003 209 294 (Pubitemid 36775376)
23. D. Lamers, S. Famulla, N. Wronkowitz, S. Hartwig, S. Lehr, D.M. Ouwens, K. Eckardt, J.M. Kaufman, M. Ryden, S. Muller, F.G. Hanisch, J. Ruige, P. Arner, H. Sell, and J. Eckel Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome Diabetes 60 2011 1917 1925
24. B.J. Lamont, and D.J. Drucker Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice Diabetes 57 2008 190 198
25. X. Liu, N. Harada, S. Yamane, L. Kitajima, S. Uchida, A. Hamasaki, E. Mukai, K. Toyoda, C. Yamada, Y. Yamada, Y. Seino, and N. Inagaki Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice Life Sci. 84 2009 876 881
26. D. Marguet, L. Baggio, T. Kobayashi, A.M. Bernard, M. Pierres, P.F. Nielsen, U. Ribel, T. Watanabe, D.J. Drucker, and N. Wagtmann Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc. Natl. Acad. Sci. U.S.A. 97 2000 6874 6879 (Pubitemid 30412807)
27. P.G. McTernan, F.M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C.L. McTernan, P.M. Clark, S.A. Smith, A.H. Barnett, and S. Kumar Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes J. Clin. Endocrinol. Metab. 88 2003 6098 6106 (Pubitemid 38033098)
28. J.J. Meier, and M.A. Nauck Incretins and the development of type 2 diabetes Curr. Diabetes Rep. 6 2006 194 201
29. H.J. Mest, and R. Mentlein Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes Diabetologia 48 2005 616 620 (Pubitemid 40591214)
30. M. Muurling, A.M. van den Hoek, R.P. Mensink, H. Pijl, J.A. Romijn, L.M. Havekes, and P.J. Voshol Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance J. Lipid Res. 45 2004 9 16 (Pubitemid 38176610)
31. M. Nabeno, F. Akahoshi, H. Kishida, I. Miyaguchi, Y. Tanaka, S. Ishii, and T. Kadowaki A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site Biochem. Biophys. Res. Commun. 434 2013 191 196
32. Y. Nakamaru, Y. Hayashi, R. Ikegawa, S. Kinoshita, B.P. Madera, D. Gunput, A. Kawaguchi, M. Davies, S. Mair, H. Yamazaki, T. Kume, and M. Suzuki Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans Xenobiotica 2013 (in press)
33. D.M. Nathan Long-term complications of diabetes mellitus N. Engl. J. Med. 328 1993 1676 1685 (Pubitemid 23157351)
34. B.A. Omar, J. Vikman, M.S. Winzell, U. Voss, E. Ekblad, J.E. Foley, and B. Ahren Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model Diabetologia 56 2013 1752 1760
35. G. Ramirez, A.D. Morrison, and P.A. Bittle Clinical practice considerations and review of the literature for the use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease Endocr. Pract. 19 2013 1025 1034
36. V.T. Samuel, Z.X. Liu, X. Qu, B.D. Elder, S. Bilz, D. Befroy, A.J. Romanelli, and G.I. Shulman Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease J. Biol. Chem. 279 2004 32345 32353 (Pubitemid 39014687)
37. T. Shimasaki, T. Masaki, K. Mitsutomi, D. Ueno, K. Gotoh, S. Chiba, T. Kakuma, and H. Yoshimatsu The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity PloS One 8 2013 e63626
38. T. Skurk, C. Alberti-Huber, C. Herder, and H. Hauner Relationship between adipocyte size and adipokine expression and secretion J. Clin. Endocrinol. Metab. 92 2007 1023 1033 (Pubitemid 46465679)
39. A.M. Van den Hoek, P.J. Voshol, B.N. Karnekamp, R.M. Buijs, J.A. Romijn, L.M. Havekes, and H. Pijl Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin Diabetes 53 2004 2529 2534 (Pubitemid 39299258)
40. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, and S. Rossner Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the Rio-Europe study Lancet 365 2005 1389 1397 (Pubitemid 40523733)
41. R.R. Wing, W. Lang, T.A. Wadden, M. Safford, W.C. Knowler, A.G. Bertoni, J.O. Hill, F.L. Brancati, A. Peters, and L. Wagenknecht Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes Diabetes Care 34 2011 1481 1486
42. N. Yasuda, T. Nagakura, K. Yamazaki, T. Inoue, and I. Tanaka Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats Life Sci. 71 2002 227 238 (Pubitemid 34595439)
43. R. Yazbeck, G.S. Howarth, and C.A. Abbott Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol. Sci. 30 2009 600 607
44. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830 (Pubitemid 34233752)